Alumni community member
Acrivon Therapeutics / Acrivon AB
Acrivon Therapeutics specializes in accelerated drug development in oncology, using a unique, predictive phospho-proteomic approach. Their patented technology platform identifies drug-tailored biomarker signatures for patient responder identification, which increases efficacy, reduces toxicity and precisely matches the therapy with patients who will benefit.
Kristina Masson, Head of Acrivon AB and Co-Founder of the Boston-based Headquarters. Between experts in the US, Sweden and Denmark, we are building our dream team to tackle one of the biggest challenges in the oncology industry. The name Acrivon is inspired by the Greek word for accurate.
Did you know?
Acrivon’s method is applicable across drug modalities and diseases!